Navidea Biopharmaceuticals Inc Net debt/EBITDA
¿Qué es el Net debt/EBITDA de Navidea Biopharmaceuticals Inc?
El Net debt/EBITDA de Navidea Biopharmaceuticals Inc es 0.38
¿Cuál es la definición de Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA de compañías en Sector Health Care en NYSEMKT en comparadas con Navidea Biopharmaceuticals Inc
¿Qué hace Navidea Biopharmaceuticals Inc?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Empresas con net debt/ebitda similar a Navidea Biopharmaceuticals Inc
- Kühne + Nagel International AG tiene Net debt/EBITDA de 0.37
- Enphase tiene Net debt/EBITDA de 0.38
- Global Technologies tiene Net debt/EBITDA de 0.38
- RoodMicrotec N.V tiene Net debt/EBITDA de 0.38
- VentriPoint Diagnostics tiene Net debt/EBITDA de 0.38
- AM Resources tiene Net debt/EBITDA de 0.38
- Navidea Biopharmaceuticals Inc tiene Net debt/EBITDA de 0.38
- Caledonia Investments Plc tiene Net debt/EBITDA de 0.38
- Tymlez tiene Net debt/EBITDA de 0.38
- Synovus tiene Net debt/EBITDA de 0.39
- Eskay Mining tiene Net debt/EBITDA de 0.39
- Foxconn Interconnect Technology tiene Net debt/EBITDA de 0.39
- DermTech tiene Net debt/EBITDA de 0.39